Advances in Organic Synthesis for Drug Discovery and Development

A special issue of Reactions (ISSN 2624-781X).

Deadline for manuscript submissions: 31 March 2026 | Viewed by 1932

Special Issue Editor


E-Mail Website
Guest Editor
Laboratory of Design and Synthesis of Bioactive Substances, Department of Pharmacy, University of São Paulo, Prof. Lineu Prestes Avenue 580, Bl.13, Butantã, SP 05508-900, Brazil
Interests: design and synthesis of bioactive drug candidates and prodrugs; organic synthesis; prodrug design

Special Issue Information

Dear Colleagues, 

The field of drug discovery is undergoing a transformative phase, with the boundaries between traditional organic synthesis, medicinal chemistry, and chemical biology becoming increasingly fluid. This Special Issue of Reactions, "Advances in Organic Synthesis for Drug Discovery and Development", will showcase groundbreaking synthetic strategies that are revolutionizing how we design, construct, and optimize bioactive molecules. From the advent of bio-orthogonal reactions and flow chemistry to the integration of machine learning in synthetic route design, modern organic synthesis is no longer limited to bond formation—it now drives molecular innovation with precision and purpose. We are particularly interested in contributions that present novel synthetic methodologies enabling the rapid generation of chemical diversity, late-stage functionalization, and access to previously elusive pharmacophores. This Special Issue will also highlight sustainable and scalable approaches, such as catalytic and green chemistry strategies. Studies offering insights into mechanism-driven design and structure–activity relationships (SARs), especially those supported by computational or data-driven tools, are welcome. We invite researchers working at the intersection of synthesis and therapeutics to contribute original research, reviews, and communications that reflect the current and future directions of drug-focused organic synthesis.

Dr. Roberto Parise-Filho
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Reactions is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • organic synthesis
  • drug discovery
  • molecular innovation
  • catalysis
  • medicinal chemistry
  • sustainable chemistry
  • pharmacophore design
  • structure–activity relationship (SAR)

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 1342 KB  
Article
Synthesis of 6-Arylaminoflavones via Buchwald–Hartwig Amination and Its Anti-Tumor Investigation
by Karinne E. Prado, Micael R. Cunha, Gabriela A. Moreira, Karoline B. Waitman, Neuza M. A. Hassimotto, Katlin B. Massirer, Monica F. Z. J. Toledo and Roberto Parise-Filho
Reactions 2025, 6(3), 42; https://doi.org/10.3390/reactions6030042 - 31 Jul 2025
Viewed by 1206
Abstract
A new series of 6-arylaminoflavones was synthesized via the Buchwald–Hartwig cross-coupling reaction, aiming to functionalize the flavone core efficiently. Reaction optimization revealed that Pd2(dba)3/XantPhos with Cs2CO3 in toluene provided the best yields, with isolated yields ranging [...] Read more.
A new series of 6-arylaminoflavones was synthesized via the Buchwald–Hartwig cross-coupling reaction, aiming to functionalize the flavone core efficiently. Reaction optimization revealed that Pd2(dba)3/XantPhos with Cs2CO3 in toluene provided the best yields, with isolated yields ranging from 8% to 95%, depending on the arylamine structure. Steric hindrance and electron-withdrawing groups at the arylamine ring impacted the reaction outcomes. Cytotoxicity assays in different human cancer cell lines indicated that substitution patterns at both the arylamine and B-rings strongly impacted biological activity. In particular, compounds bearing a 3,4-dimethoxy substitution at the B-ring and a trifluoromethyl (13c) or chlorine (13g) group at the aniline moiety exhibited enhanced cytotoxicity. These findings provide insights into the structure–activity relationship of 6-arylaminoflavones while contributing to the development of synthetic methodologies for functionalized flavones. Full article
(This article belongs to the Special Issue Advances in Organic Synthesis for Drug Discovery and Development)
Show Figures

Graphical abstract

Review

Jump to: Research

26 pages, 4424 KB  
Review
C–H Annulation in Azines to Obtain 6,5-Fused-Bicyclic Heteroaromatic Cores for Drug Discovery
by Maria Carolina Theisen, Isis Apolo Silveira de Borba, Angélica Rocha Joaquim and Fernando Fumagalli
Reactions 2025, 6(4), 72; https://doi.org/10.3390/reactions6040072 (registering DOI) - 10 Dec 2025
Abstract
Fused-bicyclic heteroaromatic cores are a common framework in drugs and other biologically active compounds. Those containing azine rings are widely used in drug discovery campaigns. Although these cores are very common, C–H functionalization of their azine moieties remains challenging, especially in annulation reactions. [...] Read more.
Fused-bicyclic heteroaromatic cores are a common framework in drugs and other biologically active compounds. Those containing azine rings are widely used in drug discovery campaigns. Although these cores are very common, C–H functionalization of their azine moieties remains challenging, especially in annulation reactions. Therefore, this review highlights the progress made over the years in C–H annulation reactions that have produced these essential 6,5-fused bicyclic heteroaromatic cores for drug discovery. For that, the review was divided according to the five-membered rings moiety (pyrrole, pyrazole, imidazole, furan, thiophen, and thiazole) fused to different azines (pyridine, pyrazine, pyridazine, pyrimidine, and triazine). Although some important advances have been made over the years, there remains a need for research in synthetic methodology to expand the use of these heteroaromatic cores in biologically active compounds. Full article
(This article belongs to the Special Issue Advances in Organic Synthesis for Drug Discovery and Development)
Show Figures

Graphical abstract

17 pages, 3157 KB  
Review
Green Strategies for the Synthesis of Heterocyclic Derivatives with Potential Against Neglected Tropical Diseases
by Vinícius Augusto Campos Péret and Renata Barbosa de Oliveira
Reactions 2025, 6(4), 66; https://doi.org/10.3390/reactions6040066 - 2 Dec 2025
Viewed by 229
Abstract
Neglected tropical diseases (NTDs) remain a significant global health burden, exacerbated by the ongoing climate emergency, which alters disease distribution and increases vulnerability in affected populations. The urgent need for novel therapeutics demands innovative approaches in drug discovery, with heterocyclic compounds serving as [...] Read more.
Neglected tropical diseases (NTDs) remain a significant global health burden, exacerbated by the ongoing climate emergency, which alters disease distribution and increases vulnerability in affected populations. The urgent need for novel therapeutics demands innovative approaches in drug discovery, with heterocyclic compounds serving as versatile scaffolds due to their diverse electronic and structural properties that enable potent biological activity. This review highlights how green chemistry principles have been applied to the construction of bioactive heterocyclic cores relevant to NTD drug development. Key sustainable methodologies are discussed, including microwave-assisted solvent-free and green-solvent reactions, ultrasound-assisted synthesis, mechanochemical one-pot multistep strategies, and the use of ionic liquids and deep eutectic solvents as environmentally benign catalysts and reaction media. By focusing on these approaches, the review emphasizes how green synthetic strategies can accelerate the development of pharmacologically relevant heterocycles while minimizing environmental impact, resource consumption, and hazardous waste generation. Full article
(This article belongs to the Special Issue Advances in Organic Synthesis for Drug Discovery and Development)
Show Figures

Figure 1

Back to TopTop